Perioperative Chemotherapy

1985 ◽  
BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Gang Xu ◽  
Hisaki Aiba ◽  
Norio Yamamoto ◽  
Katsuhiro Hayashi ◽  
Akihiko Takeuchi ◽  
...  

Abstract Background Synovial sarcoma is an aggressive but chemosensitive soft-tissue tumor. We retrospectively analyzed the efficacy of perioperative chemotherapy for synovial sarcoma with data from the nationwide database, Bone and Soft Tissue Tumor Registry in Japan. Methods This study included 316 patients diagnosed with synovial sarcoma between 2006 and 2012. Oncologic outcomes were analyzed using a Cox-hazard regression model. Moreover, the effects of perioperative chemotherapy on outcomes were evaluated using a matched-pair analysis. The oncologic outcomes of patients who did or did not receive chemotherapy were compared (cx + and cx-). Results Multivariate analysis revealed significant correlations of age (over 40, hazard ratio [HR] = 0.61, p = 0.043), margin status (marginal resection, HR = 0.18, p < 0.001 and intralesional resection, HR = 0.30, p = 0.013 versus wide resection) with overall survival; surgical margin type (marginal resection, HR = 0.14, p = 0.001 and intralesional resection, HR = 0.09, p = 0.035 versus wide resection) with local recurrence; and postoperative local recurrence (HR = 0.30, p = 0.027) and surgical margin (marginal resection, HR = 0.31, p = 0.023 versus wide resection) with distant relapse-free survival. Before propensity score matching, perioperative chemotherapy was mainly administered for young patients and patients with deeper tumor locations, larger tumors, more advanced-stage disease, and trunk location. The 3-year overall survival, local control, and distant relapse-free survival rates were 79.8%/89.3% (HR = 0.64, p = 0.114), 89.6%/93.0% (HR = 0.37, p = 0.171) and 71.4%/84.5% (HR = 0.60, p = 0.089) in the cx+/cx- groups, respectively. After propensity score matching, 152 patients were selected such that the patient demographics were nearly identical in both groups. The 3-year overall survival, local control, and distant relapse-free survival rates were 71.5%/86.0% (HR = 0.48, p = 0.055), 92.5%/93.3% (HR = 0.51, p = 0.436) and 68.4%/83.9% (HR = 0.47, p = 0.046) in the cx+/cx- groups, respectively. Conclusion This large-sample study indicated that the margin status and postoperative disease control were associated directly or indirectly with improved oncologic outcomes. However, the efficacy of perioperative chemotherapy for survival outcomes in synovial sarcoma patients was not proven in this Japanese database analysis.


2015 ◽  
Vol 148 (4) ◽  
pp. S-1118-S-1119 ◽  
Author(s):  
Eva Fuentes ◽  
Rima Ahmad ◽  
Theodore S. Hong ◽  
Eunice L. Kwak ◽  
David W. Rattner ◽  
...  

Author(s):  
Pulkit Maru ◽  
Bipradas Roy ◽  
Saugata Sen ◽  
Argha Chatterjee

AbstractAccurate preoperative nodal staging is critical in determining the appropriate therapy and prognosis for stomach cancer. A staging computed tomography should inform the treating surgeon about the nodal burden to decide the appropriate surgical plan or perioperative chemotherapy. Nodal staging is also a powerful predictor of the outcome of surgery and overall survival. Imaging of nodes is also important in the assessment of response following the chemotherapy. In this article, we will discuss lymphatic drainage of stomach and different nodal stations, identification of nodal stations on cross sectional imaging, and different types of surgical nodal clearance for gastric cancer.


2017 ◽  
Vol 35 (9) ◽  
pp. 1401-1407 ◽  
Author(s):  
Atiqullah Aziz ◽  
◽  
Jakub Dobruch ◽  
Kees Hendricksen ◽  
Luis A. Kluth ◽  
...  

2016 ◽  
Vol 223 (4) ◽  
pp. e186-e187
Author(s):  
Georgios Karagkounis ◽  
Malcolm Hart Squires ◽  
George A. Poultsides ◽  
Ryan C. Fields ◽  
Timothy M. Pawlik ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document